Openbookopenbook
Equity
Zenas BioPharma, Inc. Common Stock(ZBIO)
USD --+0.00%
Reward51Moderate
Risk32Moderate
75%Data
Revenue down 100% YoY
ZBIO
+0.0 · +0.00%
USD · NASDAQ
Zenas BioPharma, Inc. Common Stock | Healthcare
Earnings Deterioration
Market Cap:1.98Bn
ⓘ
Reward Rating
51
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
32
Moderate
Risk Assessment
6 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ZBIO to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for ZBIO, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $43.50.

What is Zenas BioPharma, Inc. Common Stock?

, a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies.

ZBIO · Verdict

Moderate reward · moderate risk

ZBIO's standout is volatility; cash flow and profitability weigh on the picture.

Based on 88% data coverage

ZBIO · Verdict

What’s working & what to watch

Strengths 1

  • Volatility95/100

    Top decile vs peers

Watchouts 2

  • Cash flow6/100

    -1724% free-cash-flow margin

  • Profitability32/100

    -3777% net margin · -137% ROE

Model-based scoring. For information only — not financial advice.

What is Zenas BioPharma, Inc. Common Stock?

, a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, and systemic lupus erythematosus. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.98B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (51)

The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap1.98B
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Insider Activity
12M windowBullish
Shares soldShares bought
0-3months
0
0
3-6months
0
2153,768 shares
$3.1M
6-9months
0
7202,845 shares
$3.7M
9-12months
0
7923,035 shares
$17.6M
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.